Browsing by Author "Ozyilkan, O."
Now showing 1 - 10 of 10
- Results Per Page
- Sort Options
Item Clinicohistopathological Features and Treatment Outcomes of Neuroendocrine Tumors; A Single Center Experience(2017) Sumbul, A. T.; Sedef, A. M.; Kose, F.; Mertsoylu, H.; Sezer, A.; Ozyilkan, O.; Abali, H.; https://orcid.org/0000-0002-5573-906X; https://orcid.org/0000-0001-8825-4918; D-4793-2014; AAD-2817-2021Item Efficacy and Safety Outcomes with Pembrolizumab (Pembro) Rechallenge for Patients (Pts) with Advanced/Metastatic Urothelial Cancer (UC) Who Responded To First-Course Treatment(2023) Koshkin, V. S.; Danchaivijitr, P.; Bae, W. K.; Semenov, A.; Ozyilkan, O.; Su, Y-L.; Arranz Arija, J. A.; Tsujihata, M.; Boegemann, M.; Hendriks, M. P.; Neciosup Delgado, S. P.; Cheng, S.; Rosenbaum, E.; Lopez, K.; Bavle, A.; Liu, C-C.; Imai, K.; Furka, A.Item Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey(2019) Sezer, A.; Ozyilkan, O.Item nextMONARCH 1: Phase 2 study of abemaciclib plus tamoxifen or abemaciclib alone in HR+, HER2-advanced breast cancer(2019) Hamiton, E.; Cortes, J.; Dieras, V.; Ozyilkan, O.; Chen, S-C.; Petrakova, K.; Manikhas, A.; Jerusalem, G.; Hegg, R.; Lu, Y.; Bear, M.M.; Johnston, E.L.; Martin, M.Item nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2-metastatic breast cancer(2020) Hamilton, E.P.; Cortes, J.; Ozyilkan, O.; Chen, S-C.; Petrakova, K.; Manikhas, A.; Jerusalem, G.; Hegg, R.; Huober, J.; Chapman, S.C.; Yang, Z.; Chen, Y.; Johnston, E.L.; Martin, M.; 0000-0001-8825-4918; AAD-2817-2021Item nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, Her2-metastatic breast cancer(2021) Huober, J.; Hamilton, E.; Cortes, J.; Ozyilkan, O.; Chen, S.C.; Petrakova, K.; Manikhas, A.; Jerusalem, G.; Hegg, R.; Chapman, S.; Yang, Z.; Chen, Y.; Johnston, E.; Martin, M.Item Predictive and prognostic role of T-regulatory cells in resected non-small cell lung cancer(2016) Kose, F.; Findikcioglu, A.; Canpolat, T.; Sedef, A.M.; Besen, A.; Mertsoylu, H.; Ozyilkan, O.; Abali, H.Item PROGNOSTIC ROLE OF T-REGULATORY CELLS IN COMPLETELY RESECTED EARLY STAGE NON-SMALL CELL LUNG CARCINOMA(2015) Kose, F.; Abali, H.; Findikcioglu, A.; Canpolat, T.; Besen, A.A.; Sumbul, A.T.; Mertsoylu, H.; Sedef, A.M.; Ozyilkan, O.Item Prolonged Use of Bevacizumab May Cause Extensive Coronary Artery Thrombosis(2014) Muallaoglu, S.; Disel, U.; Tekin, A.; Mertsoylu, H.; Abali, H.; Ozyilkan, O.; https://orcid.org/0000-0002-6242-2802; https://orcid.org/0000-0002-5658-870X; https://orcid.org/0000-0002-1932-9784; https://orcid.org/0000-0001-5596-0920; https://orcid.org/0000-0001-8825-4918; 24965427; IVU-7523-2023; ABD-7304-2021; M-9530-2014; D-7660-2016; AAD-2817-2021Item Treatment Outcomes of Breast Cancer Lung Metastasis Treated with Stereotactic Body Radiotherapy(2020) Guler, O. C.; Sari, S. Y.; Gultekin, M.; Yildirim, B. A.; Ozyilkan, O.; Yildiz, F.; Onal, C.; 0000-0001-6661-4185; V-5717-2017; ABX-1273-2022; HOC-5611-2023